Clinical Scorecard: Outcomes and Frequency of Salvage Cystectomy Following Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

At a Glance

Key Highlights

• BST with trimodal therapy (TMT) offers oncologic outcomes comparable to primary RC in selected patients.
• A significant proportion of patients undergoing BST may require salvage radical cystectomy due to non-response or local recurrence.
• Salvage cystectomy after BST is associated with increased surgical complexity and potential for higher complication rates due to irradiated tissues.

Guideline-Based Recommendations

Diagnosis

• Include patients with ≥ cT2N0/xM0 bladder cancer eligible for all treatment modalities at initial decision.
• Exclude patients unfit for surgery or elderly patients with limited treatment options from BST consideration.

Management

• Use maximal TURBT followed by radiochemotherapy as the preferred bladder-sparing approach.
• Offer trimodal therapy as an alternative to primary radical cystectomy for well-informed, compliant patients desiring bladder preservation.
• Perform salvage radical cystectomy in cases of BST failure defined by non-response within 6 months or local recurrence.

Monitoring & Follow-up

• Monitor patients closely for disease response within 6 months post-BST to identify non-responders early.
• Assess for local recurrence through intravesical surveillance.
• Evaluate perioperative complications within 30 days following salvage cystectomy.

Risks

• Increased surgical risks and complications due to tissue fragility from prior radiotherapy in salvage cystectomy.
• Potential differences in quality of life outcomes after salvage cystectomy compared to primary radical cystectomy.
• Higher likelihood of salvage cystectomy requirement in patients with multifocal tumors, carcinoma in situ, or hydronephrosis.

Patient & Prescribing Data

Patients with muscle-invasive bladder cancer eligible for bladder-sparing therapy and salvage cystectomy if needed.

Bladder-sparing therapy is generally preferred by patients due to minimal invasiveness and manageable toxicity, but requires careful selection and counseling about the possibility and risks of salvage cystectomy.

Clinical Best Practices

• Select patients carefully for bladder-sparing therapy based on tumor characteristics (unifocal cT2, fully resectable, no carcinoma in situ or hydronephrosis).
• Ensure patients are well-informed and compliant with treatment and follow-up protocols.
• Use standardized definitions for non-response and local recurrence to guide timely salvage cystectomy.
• Consider the increased complexity and risks of salvage cystectomy when counseling patients and planning surgery.
• Exclude elderly or unfit patients from bladder-sparing therapy protocols where salvage cystectomy is unlikely to be feasible.

References

• Preferred Reporting Items for Meta-Analyses of Observational Studies in Epidemiology Statement
• PROSPERO Registration CRD42020187685